Teleflex Incorporated

TFX

$139.96

-0.72%

2026-09-03 16:00:03 EDT-$1.01

Healthcare

Medical - Instruments & Supplies

NYSE

Active Trading

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial ...

Price Action of TFX

$139.96

-0.72%-$1.01

High—

Low—

52W High-3.2%

Rel. vol—

Interval

Range6.4h

Volume—SMA5SMA10

—

Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is a leading global medical technology company with a rich history dating back to 1943. The company focuses on developing innovative, single-use medical devices that address unmet clinical needs in critical care and surgical environments. Teleflex's product portfolio is diverse, encompassing several key categories. ...Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is a leading global medical technology company with a rich history dating back to 1943. The company focuses on developing innovative, single-use medical devices that address unmet clinical needs in critical care and surgical environments. Teleflex's product portfolio is diverse, encompassing several key categories. In vascular access, the 'Arrow' brand offers catheters, navigation systems, and intraosseous access devices. Interventional cardiology and radiology products include coronary catheters, such as the Arrow, Guideline, and Trapliner lines, the Manta vascular closure device, and Arrow Oncontrol systems for peripheral intervention. Anesthesia and surgical products include metal and polymer ligation clips, fascial closure systems, and surgical instruments. Teleflex also provides respiratory care products such as oxygen and aerosol therapy devices, spirometry, and ventilation management. Notably, the company's interventional urology segment offers the UroLift System, a minimally invasive treatment for benign prostatic hyperplasia. Teleflex serves a broad customer base, including hospitals, healthcare providers, emergency medical services, military health organizations, medical device OEMs, and the home care market. As of 2026, the company employs approximately 15,500 people worldwide, with revenue estimated at $2.8 billion. Teleflex continues to innovate, driven by a purpose to improve the health and quality of people's lives. Its financial metrics show a market cap of around $5.98 billion, with a focus on maintaining a strong balance sheet and investing in R&D. Despite recent challenges in profitability, the company remains a key player in the medical device industry, with a commitment to growth and innovation.ExpandCollapse

Founded

1943

Employees

15500

CEO

Jason Weidman

Full Name

Teleflex Incorporated

Sector

Healthcare

Industry

Medical - Instruments & Supplies

ROE

-31.83%

Market Cap

$6.20B

Current Ratio

2.60

WACC

6.75%

ROIC

-5.72%

Contact Information

https://www.teleflex.com

610 225 6800

550 East Swedesford Road, Wayne, PA 19087-1603

Key Metrics of TFX

Snapshot

Latest / TTM · 6 periods

Market Cap

$6.20B

ROCE

1.4%

EV / EBITDA

-36.83x

-2.7% YoY

FCF Yield

6.3%

+1.8% YoY

Cash Conversion Cycle

114.5d

Current Ratio

2.60

Quick take

TTM —

Positive CCC

Financial Highlights of TFX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

53.8%

Net Margin

-39.6%

P/E Ratio

-6.01x

n/a

Debt / Equity

0.99

n/a

Current Ratio

2.60

Dividend Yield

1.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of TFX

Upcoming

Sep 30, 2026In 26 days
Dividend payment
$1.36 per share
Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $1.90 · Revenue $565.37M · 9 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $2.18 · Revenue $584.24M · 9 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $7.20 · Revenue $2.27B · 8 analysts

Recent history

Aug 14, 2026
Ex-dividend date
$1.36 per share
Aug 6, 2026
Q2 FY2026 · Results reported
EPS $2.28 · Revenue $570.33M
View filing
May 7, 2026
Q1 FY2026 · Results reported
EPS $-0.18 · Revenue $548.26M
View filing
Feb 27, 2026
FY2025 · Annual results
EPS $-20.25 · Revenue $1.99B
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-9.24 · Revenue $913.02M
View filing
Jul 31, 2025
Q2 FY2025 · Results reported
EPS $2.77 · Revenue $780.89M
View filing

Financial Statements of TFX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$2.0B	-34.6%	+4.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-905.6M	-1399.8%	+1351.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+56.2%	+0.7%	+3.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+12.8%	+159.0%	+187.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-45.4%	-2087.7%	+1302.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$245.4M	-51.8%	+145.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+12.3%	-26.3%	+136.4%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	87.2%	+112.6%	+13.6%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.54x	+12.3%	+1.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$6.9B	-2.1%	+0.1%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-20.25 vs 14.02	-244.5%	2.28 vs 1.90	+20.0%
Revenue Surprise	$2.0B vs $3.3B	-39.6%	$570.3M vs $565.4M	+0.9%

Insider Transactions of TFX

Acquisitions (A)

Since May 15, 2026

Disposals (D)

Since May 15, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 8, 2026	RANDLE STUART A	director	Common Stock	A	4,663	—
Jun 8, 2026	RANDLE STUART A	director	Common Stock	A	995	—
Jun 8, 2026	RANDLE STUART A	director	Stock Option / (Right to Buy)	A	2,192	$131.74
Jun 8, 2026	Weidman Jason R.	director, officer: President and CEO	Common Stock	A	53,983	—
Jun 8, 2026	Weidman Jason R.	director, officer: President and CEO	Stock Option / (Right to Buy)	A	26,071	$131.74

Earnings Call Transcript of TFX

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good morning, ladies and gentlemen, and welcome to the Teleflex Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and will be available on the company's website for replay shortly. And now I'll turn the call over to Mr. Lawrence Keusch. Vice President of Investor Relations and Strategy Development. Please go ahead. Lawrence Keusch: Good morning, everyone, and welcome to the Teleflex Incorporated Second Quarter 2026 Earnings Conference Call. The press release and slides to accompany this call are available on our website at teleflex.com. As a reminder, a replay will be available on our website. Those wishing to access the replay can refer to our press release from this morning for details. Participating on today's call are Jason Weidman, President and Chief Executive Officer; and John Deren, Executive Vice President and Chief Financial Officer. Jason and John will provide prepared remarks, and then we will open the call to Q&A. Before we begin, I'd like to remind you that some of the matters discussed in the conference call will contain forward-looking statements regarding future events as outlined in the slides posted to the Investor Relations section of the Teleflex website. We wish to caution you that such statements are, in fact, forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ materially include, but are not limited to, factors referenced in our press release today as well as our filings with the SEC, including our Form 10-K which can be accessed on our website. Now I'll turn the call over to Jason for his remarks. Jason Weidman: Thank you, Larry, and good morning, everyone. Let me begin by saying it's been a great start to my time at Teleflex. Over the past 2 months, I've really focused on learning our business, our products and our organization. This has meant considerable time visiting many of our sites around the globe, meeting with employees across the organization, engaging with customers and physicians and reviewing the company's portfolio, operating priorities and long-term growth opportunities. While it's still early, a couple of things have stood out immediately to me. Our employees are fantastic. They're dedicated. There's real pride and belief in what we do for patients, and they're eager to build on our accomplishments and drive execution. Second is the strength of Teleflex's underlying businesses, we have great products with market-leading positions in many important categories, strong brands and a substantial global commercial footprint. My initial observations have also reinforced my belief that there is substantial opportunity ahead for Teleflex and that we have the right foundation to capture this potential. We remain focused on executing key initiatives underway, including completing the announced …

Leadership Team of TFX

12 executives

Name	Title	Compensation	Gender	Year Born	Status
John R. Deren	Executive Vice President & Chief Financial Officer	USD 824,600	Male	1968	Active
Daniel V. Logue	Corporate Vice President, General Counsel & Secretary	USD 694,888	Male	1974	Active
Cameron Hicks	Corporate Vice President of Human Resources & Communications	USD 664,042	Male	1965	Active
Stuart A. Randle	CEO, Interim President & Director	USD 113,500	Male	1960	Active
Jake Newman	President & GM of Vascular and Emergency Medicine	—	Male	—	Active
Jason Weidman	President, CEO & Director	—	Male	—	Active
Howard Cyr	Corporate Vice President & Chief Compliance Officer	—	Male	—	Active
James Ferguson	President & GM of Surgical	—	Male	—	Active
Lawrence Soren Keusch	Vice President of Investor Relations & Strategy Development	—	Male	—	Active
Matthew James	President & GM of Interventional	—	Male	—	Active
Matt Tomkin	Vice President of Corporate Development	—	Male	—	Active
Timothy F. Duffy	Vice President & Chief Information Officer	—	Male	—	Active

Recent News of TFX

Seeking Alpha8/6/2026Neutral

Teleflex Incorporated (TFX) Q2 2026 Earnings Call Transcript

Zacks Investment Research8/6/2026Neutral

Teleflex (TFX) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research8/6/2026Neutral

Teleflex (TFX) Surpasses Q2 Earnings and Revenue Estimates

Teleflex (TFX) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $3.73 per share a year ago.

Business Wire8/6/2026Neutral

Teleflex Announces Quarterly Dividend

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 30, 2026, to shareholders of record at the close of business on August 14, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to bec.

Business Wire8/6/2026Neutral

Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period Adjusted diluted EPS fr.

Historical Employee Count of TFX

Current

15,500

Change

+9.93%

Minimum

14,000

Maximum

15,500

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	15,500	10-K	Feb 27, 2026	View
Dec 31, 2024	14,100	10-K	Feb 28, 2025	View
Dec 31, 2023	14,500	10-K	Feb 23, 2024	View
Dec 31, 2022	15,500	10-K	Feb 23, 2023	View
Dec 31, 2021	14,000	10-K	Mar 1, 2022	View

Related stocksMedical - Instruments & Supplies

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Teleflex Incorporated